Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis

Journal of Bone and Mineral Research

Volumn 19, Issue 8, 2004, Pages 1241-1249

  Chesnut III, Charles H ^a,l   Skag, Arne ^b   Christiansen, Claus ^c   Recker, Robert ^d   Stakkestad, Jacob A ^e   Hoiseth, Arne ^f   Felsenberg, Dieter ^g   Huss, Hermann ^h   Gilbride, Jennifer ⁱ   Schimmer, Ralph C ^j   Delmas, Pierre D ^k  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Center for Clinical Trials   (Norway)

^c CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^d CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CECOR AS   (Norway)

^f Oslo Department   (Norway)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h F Hoffmann La Roche Ltd ^*

ⁱ ROCHE PRODUCTS LTD   (United Kingdom)

^j F HOFFMANN LA ROCHE LTD   (Switzerland)

^k UNIVERSITÉ LYON 1   (France)

^l UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

more..

Author keywords

Bisphosphonates; Ibandronate; Osteoporosis; Vertebral fracture

Indexed keywords

IBANDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE;

ARTICLE; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FRACTURE; FRAGILITY FRACTURE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MORPHOMETRICS; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STATISTICAL SIGNIFICANCE; VERTEBRA FRACTURE; AGED; BODY HEIGHT; BONE; BONE DENSITY; CHEMISTRY; DRUG EFFECT; FEMUR; LUMBAR VERTEBRA; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATIENT SELECTION; PELVIC GIRDLE; PROSPECTIVE STUDY; RISK FACTOR; SPINE FRACTURE; TREATMENT OUTCOME;

AGED; BODY HEIGHT; BONE AND BONES; BONE DENSITY; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; FEMUR; FRACTURES, BONE; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT SELECTION; PELVIC BONES; PROSPECTIVE STUDIES; RISK FACTORS; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 4544262219     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.040325     Document Type: Article

References (43)

1. Melton LJ, Atkinson EJ, O'Fallon WM, Walmer HW, Riggs BL 1991 Long-term fracture risk prediction with bone mineral measurements made at various skeletal sites. J Bone Miner Res 6:S1; S136.
2. Jones G, Nguyen T, Sambrook PN, Kelly PJ, Gilbert C, Eisman JA 1994 Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos Int 4:277-282.
3. Barrett-Connor E 1995 The economic and human costs of osteoporotic fracture. Am J Med 98(Suppl 2A):3S-8S.
4. Russell RGG, Croucher PL, Rogers MJ 1999 Bisphosphonates: Pharmacology, mechanisms of action and clinical uses. Osteoporos Int 9(Suppl 2):S66-S80.
5. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yanover MJ, Mysiw WJ, Kohse L, Rao MB, Steiger P, Richmond B, Chesnut CH III 1990 Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79.
6. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541.
7. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352.
8. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY, Hip Intervention Program Study group 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study group. N Engl J Med 344:333-340.
9. de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK 1996 Esophagitis associated with the use of alendronate. N Engl J Med 335:1016-1021.
10. Ettinger B, Pressman A, Schein J 1998 Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care 4:1377-1382.
11. Papapoulos SE 2001 Bisphosphonates in the management of postmenopausal osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds.) Osteoporosis, 2nd ed. Academic Press, San Diego, CA, USA, pp. 631-649.
12. Gertz BJ, Hollard SD, Kline WF 1993 Clinical pharmacology of alendronate sodium. Osteoporos Int 3(Suppl 3):13-16.
13. Caro J, Huybrechts K, Ishak K, Naujoks C 2002 The impact of adherence to osteoporosis therapy on fracture rates in actual practice. Value Health 5:127 (abstract).
14. Kendler DL, Diez-Perez A, Gaines KA, Verbruggen N, Melton ME 2002 Patient preference of once weekly or daily administration of alendronate (Fosamax) for osteoporosis: a randomized crossover study. Osteoporos Int 13(Suppl 1):S32 (abstract).
15. Palmisano J, Melton M, Lewiecki EM, Rosen R, Bockman RS, Dinh AC, Smith ME, Wang L, Keene W 2002 Preference study of alendronate 70 mg once weekly and alendronate 10 mg once daily in postmenopausal women with osteoporosis. Osteoporos Int 13(Suppl 1):S36 (abstract).
16. Bone HG, Adami S, Rizzoli R, Favus M, Ross PD, Santora A, Prahalada S, Daifotis A, Orloff J, Yates J 2000 Weekly administration of alendronate: Rationale and plan for clinical assessment. Clin Ther 22:15-28.
17. Muhlbauer RC, Bauss F, Schenk R, Janner M, Bosies E, Strein K, Fleisch H 1991 BM21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6:1003-1011.
18. Bauss F, Lalla S, Endele R, Hothorn LA 2002 Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol 29:2200-2208.
19. Monier-Faugere MC, Geng Z, Paschalis EP, Qi Q, Arnala I, Bauss F, Boskey AL, Malluche HH 1999 Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: Effects on bone morphometry and mineral properties. J Bone Miner Res 14:1768-1778.
20. Smith SY, Recker R, Hannan M, Müller R, Bauss F 2003 Intermittent IV administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 32:45-55.
21. Thiébaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, Schoter KH 1997 Three monthly IV injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103:298-307.
22. Ravn P, Clemmesen B, Riis BJ, Christiansen C 1996 The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis. A 1-year, randomized, double-blind, placebo-controlled, dose-finding study. Bone 19:527-533.
23. Riis BJ, Ise J, Von Stein T, Bagger Y, Christiansen C 2001 Ibandronate: A comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 16:1871-1878.
24. Schimmer RC, Bauss F 2003 Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: A review of three phase II studies. Clin Ther 25:19-34.
25. Ross PD 1995 Morphometric criteria for vertebral fractures based on the individual's vertebral dimensions. In: Genant HK, Jergas M, van Nuijk C (eds.) Vertebral Fracture in Osteoporosis. Radiology Research and Education Foundation, San Francisco, CA, USA, pp. 205-213.
26. Kiel D 1995 Assessing vertebral fractures. National Osteoporosis Foundation Working Group on Vertebral Fractures. J Bone Miner Res 10:518-523.
27. Genant HK, Engelke K, Fuerst T, Gluer CC, Grampp S, Harris ST, Jergas M, Lang T, Lu Y, Majumdar S, Mathur A, Takada M 1996 Noninvasive assessment of bone mineral and structure: State of the art. J Bone Miner Res 11:707-730.
28. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C 1994 Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 40:2022-2025.
29. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700.
30. Rosenquist C, Qvist P, Bjarnason N, Christiansen C 1995 Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem 41:1439-1445.
31. Rosalki SB, Foo AY, Burlina A, Prellwitz W, Stieber P, Neumeier D, Klein G, Poppe WA, Bodenmuller H 1993 Multicenter evaluation of Iso-ALP test kit for measurement of bone alkaline phosphatase activity in serum and plasma. Clin Chem 39:648-652.
32. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR 2000 Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118-4124.
33. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280:2077-2082.
34. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate phase III Osteoporosis Treatment study group. N Engl J Med 333:1437-1443.
35. Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B 1999 Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Fosamax International Trial study group. Osteoporos Int 9:461-468.
36. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) study group. Osteoporos Int 11:83-91.
37. Delmas PD, Balena R, Confavreux E 1997 Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer; a double-blind placebo-controlled study. J Clin Oncol 15:955-962.
38. Passeri M, Baroni MC, Pedrazzoni M, Pioli G, Barbagallo M, Costi D, Biondi M, Girasole G, Arlunno B, Palummeri E 1991 Intermittent treatment with IV 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHButBP) in the therapy of postmenopausal osteoporosis. Bone Miner 15:237-248.
39. Thiébaud D, Burckhardt P, Melchior J, Eckert P, Jacquet AF, Schnyder P, Gobelet C 1994 Two years effectiveness of IV pamidronate (APD) versus oral fluoride for osteoporosis occurring in the menopause. Osteoporos Int 4:76-83.
40. Filipponi P, Pedetti M, Fedeli L, Cini L, Palumbo R, Boldrini S, Massoni C, Cristallini S 1995 Cyclical clodronate is effective in preventing postmenopausal bone loss: A comparative study with transcutaneous hormone replacement therapy. J Bone Miner Res 10:697-703.
41. Storm T, Thamsborg G, Steiniche T, Genant HK, Sørenson OH 1990 Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271.
42. Adami S, Felsenberg D, Christiansen C, Robinson J, Lorenc RS, Mahoney P, Coutant K, Schimmer RC, Delmas PD 2004 Efficacy and safety of ibandronate given by IV injection once every 3 months. Bone 34:881-889.
43. Recker R, Stakkestad JA, Chesnut CH III, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer RC, Delmas PD 2004 Clinical assessment of IV ibandronate injection once every 3 months in postmenopausal osteoporosis. Bone 34:890-894.